Skip to content

Ischemic Postconditioning Technology For Prevention of Contrast-Induced Acute Kidney Injury in Patients With acute ST Segment Elevation Myocardial Infarction

Ischemic Postconditioning Technology For Prevention of Contrast-Induced Acute Kidney Injury in Patients With acute ST Segment Elevation Myocardial Infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-ICR-15006590
Enrollment
Unknown
Registered
2015-06-10
Start date
2015-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

contrast-induced acute kidney injury

Interventions

The control group:conventional primary PCI
Treatment group:ischemia postconditioning+conventional primary PCI

Sponsors

Third Central Hospital of Tian Jin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: This study is a prospective, randomized, single-blind, controlled trial. From July 2015 to December 2015, all consecutive patients with STEMI who are candidates for primary PCI at our institution will be considered for enrollment in the present study. Eligible patients will be randomly assigned by a ratio of 1:1 to receive ischemia postconditioning and conventional primary PCI (Treatment group),or conventional primary PCI (control group). Inclusion Criteria: 1. Age>=18 years old, Diagnosed with ASTEMI; 2. Onset time of ASTEMI<12h, Undergoing Primary PCI; 3. Shock occurred in 36 hours after AMI or Cardiac shock occurred within 18 hours; 4. CAG shows that TIMI flow grade of infarction related artery(IRA) is level 0.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1. CAG shows that TIMI flow grade of IRA is level 1-3; 2. There is reverse blood flow from collateral circulation in distal section of IRA; 3. A history of Old Myocardial Infarction, PCI and CABG; 4. Abnormal coagulation function; 5. All kinds of acute or chronic infection; with malignant tumor.

Design outcomes

Primary

MeasureTime frame
Serum creatinine;estimated glomerular filtration rate;The incidence of CI-AKI;

Secondary

MeasureTime frame
The incidence of MACE;

Countries

China

Contacts

Public Contactyingwu liu
tj3zxxzzx@163.com+86 15620059248

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026